Compare Cytokinetics Inc (CYTK) vs Eos Energy Enterprises Inc (EOSE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Eos Energy Enterprises Inc — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Eos Energy Enterprises Inc trades at $2.81 (market cap $1.13B). The key difference: Cytokinetics Inc is far larger — about 7.5× Eos Energy Enterprises Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Eos Energy Enterprises Inc for 16 Days on average.
| CYTK | EOSE | |
|---|---|---|
Market Cap | $8.50B | $1.13B |
Volume | 2,395,556 | 17,918,777 |
Sector | Health | Industrials |
52-Week High | $87.26 | $19.19 |
52-Week Low | $54.76 | $2.77 |
Typical Hold Time | 19 Days | 16 Days |
Enterprise Value | $8.60B | $1.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Eos Energy Enterprises (EOSE) trades at $3.10, down 4.91% on the day, with a bearish technical signal from moving averages. The company is in a high-growth phase, with revenue surging from $114.20 million in 2025 to $214 million in 2026, though it remains deeply unprofitable with a net income margin of -246.76%. Recent positive developments include a major partnership with Google and a $87 million Department of Energy loan advance to expand production capacity.
The outlook is a mix of high growth potential and significant financial risk. Analyst consensus is a 'Buy' with a $7.10 price target, implying substantial upside, but the stock carries execution risk as the company burns cash to scale. Investors are betting on EOSE capturing market share in long-duration energy storage, but must tolerate volatility and ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →
